knowledge -WSS

knowledge

author：leisure time 2025-09-03 07:54:45 - browse：7

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

WSS

Criminal prosecution for violating HIPAA: an emerging threat

Judge orders hearing on Trump's motion to disqualify Fulton County DA

Doctors in states that ban abortion can still help patients

Putin woos African leaders at a summit in Russia with promises of expanding trade and other ties

American TikTok star stuck in Dubai for months following rental car altercation

Big Tobacco's 'harm reduction': Is it for real, or a sham?

hotspot

knowledge

focus

Sports medicine is finally prioritizing gender equality

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

Medicare proposal to cover medical devices draws a mixed reaction

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

ChatGPT in medicine: STAT answers readers' burning questions

Solving academic medical centers' existential crisis

Peter Hotez and the public health issue of online harassment

Europe is fastest

In Memoriam: Notable people who died in 2023

Doctors increasingly discourage vaping amid mounting health concerns

knowledge

Many immigrants are left out of maternal health programs

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Poland's lawmakers approve a divisive law on Russian influence

'Weather

Judge orders hearing on Trump's motion to disqualify Fulton County DA

Cytokinetics CEO stresses company can launch heart drug on its own

entertainment

hotspot

focus

Wikipedia